Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Priority to UY27441ApriorityCriticalpatent/UY27441A1/en
Publication of UY27441A1publicationCriticalpatent/UY27441A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere a una formulación de inhalación que comprende un compuesto seleccionado entre una clase particular de 5,6-dihidro- pirazolo (3,4-c)-1,2,4- triazolo (4,3- a) piridinas, que es capaz de liberar el compuesto en forma de partículas sólidas finas en el pulmón, y al uso de tal formulación en el tratamiento de ciertas enfermedades tales como las enfermedades respiratorias y los compuestos que son útiles en la invención son los compuestos de fórmula (I) y las sales farmacéuticamente aceptables de los mismos.The present invention relates to an inhalation formulation comprising a compound selected from a particular class of 5,6-dihydropyrazolo (3,4-c) -1,2,4-triazolo (4,3- a) pyridines , which is capable of releasing the compound in the form of fine solid particles in the lung, and to the use of such a formulation in the treatment of certain diseases such as respiratory diseases and the compounds that are useful in the invention are the compounds of formula ( I) and pharmaceutically acceptable salts thereof.
UY27441A2002-09-102002-09-10
USE OF COMPOUNDS IN A DRY POWDER INHALER.
UY27441A1
(en)
Compounds derived from [1,2,4] triazolo [1,5-a] pyridine, jak inhibitors; pharmaceutical composition; pharmaceutical kit; its use in the treatment of diseases such as cancer, diabetes, Alzheimer's disease, liver disease, CNS disorders, among others.